Oppenheimer & Co. Inc. Sells 124,355 Shares of Kenvue Inc. $KVUE

Key Points

• Oppenheimer & Co. sold 124,355 shares of Kenvue in Q4, cutting its stake by 49.3% to 127,811 shares worth $2.205 million as of the latest 13F filing.
• Kenvue beat quarterly estimates with $0.27 EPS (vs. $0.22 est.) and $3.78 billion in revenue, and announced a quarterly dividend of $0.2075 (annualized $0.83) for a yield of 4.8%, though its payout ratio is a high 107.8%.
• Institutional ownership is concentrated (97.64%), led by Vanguard with about 234.95 million shares (~$4.05 billion), while analysts overwhelmingly rate the stock a "Hold" with a consensus price target of $19.33 and several recent downgrades.

Oppenheimer & Co. Inc. cut its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 49.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 127,811 shares of the company's stock after selling 124,355 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Kenvue were worth $2,205,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Kenvue by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company's stock worth $4,052,913,000 after buying an additional 1,604,040 shares during the last quarter. American Century Companies Inc. lifted its position in Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company's stock worth $601,267,000 after buying an additional 6,781,640 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Kenvue by 13.5% in the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company's stock worth $375,377,000 after buying an additional 2,747,952 shares during the last quarter. Van ECK Associates Corp lifted its position in Kenvue by 101.3% in the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company's stock worth $298,008,000 after buying an additional 9,240,434 shares during the last quarter. Finally, Amundi lifted its position in Kenvue by 21.6% in the third quarter. Amundi now owns 17,645,761 shares of the company's stock worth $277,012,000 after buying an additional 3,135,871 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

KVUE stock opened at $17.15 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The business has a 50-day moving average price of $17.72 and a 200 day moving average price of $17.19. The company has a market capitalization of $32.92 billion, a P/E ratio of 22.27, a PEG ratio of 3.96 and a beta of 0.55. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same period in the previous year, the company posted $0.26 earnings per share. The firm's quarterly revenue was up 3.2% on a year-over-year basis. As a group, equities research analysts forecast that Kenvue Inc. will post 1.1 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date is Wednesday, May 13th. Kenvue's payout ratio is 107.79%.

Analyst Ratings Changes

A number of analysts recently issued reports on KVUE shares. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 14th. Jefferies Financial Group downgraded Kenvue from a "buy" rating to a "hold" rating and lowered their price target for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Argus upgraded Kenvue to a "hold" rating in a research report on Friday, March 6th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Kenvue in a research report on Wednesday, April 8th. Finally, Canaccord Genuity Group boosted their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a "hold" rating in a research note on Wednesday, February 18th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, Kenvue has an average rating of "Hold" and a consensus price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.